ID   BT138
AC   CVCL_E6EX
SY   CPDM_0814X
RX   PubMed=22343896;
WW   Provider; CPDM; CPDM_0814X; https://docs.google.com/spreadsheets/d/1sxAPF3p6xK2h01zaiQ1ExCWwzhxeZ-oDLN3s3LeJq98/edit?usp=sharing
CC   Part of: Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute cell line panel.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (PubMed=22343896).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing; Low read coverage.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C4326; Anaplastic oligodendroglioma
DI   ORDO; Orphanet_251630; Anaplastic oligodendroglioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=22343896; DOI=10.1038/nature10898; PMCID=PMC3656605;
RA   Koivunen P., Lee S., Duncan C.G., Lopez G.Y., Lu G., Ramkissoon S.H.,
RA   Losman J.-A., Joensuu P., Bergmann U., Gross S., Travins J., Weiss S.,
RA   Looper R.E., Ligon K.L., Verhaak R.G.W., Yan H., Kaelin W.G. Jr.;
RT   "Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to
RT   EGLN activation.";
RL   Nature 483:484-488(2012).
//